Physician profile
Daniel G Torres
NPI 1629002860
$23,301.30
in general payments reported to CMS, 2019-2025
38 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,913 · 2020: $1,578 · 2021: $2,368 · 2022: $2,094 · 2023: $2,807 · 2024: $2,861 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,278 · Education: $71.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,277.66 |
| Education | $71.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,596.50 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Amgen INC. | $2,419.83 | 2019-2025 | Otezla, Krystexxa, Enbrel |
| Astrazeneca Pharmaceuticals LP | $1,454.23 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $1,262.40 | 2019-2025 | Benlysta, Nucala, Shingrix |
| Pfizer INC. | $1,080.13 | 2019-2025 | |
| Ucb, INC. | $1,052.81 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $826.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $797.29 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $778.66 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $590.66 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Horizon Therapeutics Plc | $560.36 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.87 | 2019-2025 | Ofev, Cyltezo, Jardiance |
| Sobi, INC | $375.46 | 2019-2025 | |
| Genzyme Corporation | $355.45 | 2019-2025 | |
| Novo Nordisk INC | $200.21 | 2021-2024 | Wegovy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $194.18 | 2023-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $146.39 | 2023-2024 | Idacio |
| Mallinckrodt Enterprises LLC | $122.04 | 2019 | |
| Merck Sharp & Dohme LLC | $105.12 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $102.32 | 2023-2024 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $96.24 | 2020-2025 | Acthar |
| Sandoz INC. | $92.53 | 2023-2024 | Hyrimoz |
| Celgene Corporation | $80.48 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $48.93 | 2021-2025 | Tremfya |
| Genentech USA, INC. | $41.16 | 2024-2025 | Actemra, Gazyva |
| Radius Health, INC. | $40.36 | 2019-2025 | Tymlos |
| Pacira Therapeutics, INC. | $38.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $37.51 | 2021-2022 | |
| Medexus Pharma, INC. | $36.42 | 2019 | |
| Celltrion USA INC. | $32.63 | 2023-2024 | Yuflyma, Zymfentra |
| Bioventus LLC | $24.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.53 | 2024 | Uptravi, Opsumit |
| Antares Pharma, INC. | $20.91 | 2019 | |
| Hologic Sales and Service, LLC | $17.82 | 2022 | |
| Braeburn INC. | $16.63 | 2024 | Brixadi |
| Biocon Biologics INC | $16.43 | 2024 | Hulio |
| Lucid Diagnostics INC. | $14.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.